Regulus Therapeutics, the microRNA drugs joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week disclosed that it is pricing its initial public offering of 11.25 million shares at $4 a share, for a total value of $45 million.
The company said it has also granted the underwriters of the offering the option to buy an additional 1.7 million shares at the $4 offering price. If exercised, the option would boost the value of the IPO to $51.75 million.
The company anticipates going public this week under the symbol “RGLS.”
Previously, Regulus had said in a filing with the US Securities and Exchange Commission that it was considering floating 4.5 million shares at between $10 and $12 apiece (GSN 9/13/2012).